Wasdell lab expansion follows €30M new plant project in Ireland

The U.K.-based Wasdell Group is expanding a facility in Newcastle, in part because of its planned move into sterile manufacturing this year. (Wasdell)

The Wasdell Group, a U.K.-based provider of services to pharma clients, will invest a half-million pounds in a laboratory project that will support its pharma manufacturing work, including its move into sterile manufacturing this year.

The £500,000 ($671,000), 1,200-square-foot facility at its Newcastle site, will allow the company to provide in-house microbiological and analytical services to its customers and will support its manufacturing, packaging and quality control (QC) teams, it said in an announcement Thursday.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“We’ve seen a notable increase in demand for analytical support from our existing clients and the investment in our microbiological capabilities has been driven by our planned move into the manufacture of sterile products later this year,” Daniel Tedham, managing director at Wasdell, said in a statement.  

The Newcastle expansion follows its decision last fall to build a new €30 million pharmaceutical facility in Dundalk, Ireland, which will offer QC import testing, a variety of current and novel packaging technologies, as well as storage and distribution.

That 70,000-square-foot facility will employ 300 when it is complete in fourth-quarter 2018 and will incorporate serialization technology to meet new regulations. It is Wasdell’s first facility outside of the U.K. and was initiated to ensure its release testing of products for the European market in the event of a hard Brexit.

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.